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PEXPEDITED REVIEWS
Coronary Artery Calcification and
Changes in Atheroma Burden in
Response to Established Medical Therapies
Stephen J. Nicholls, MBBS, PHD, FRACP, FACC,*†‡ E. Murat Tuzcu, MD, FACC,*
Kathy Wolski, MPH,* Ilke Sipahi, MD,* Paul Schoenhagen, MD,*§ Timothy Crowe, BS,*
Samir R. Kapadia, MD, FACC,* Stanley L. Hazen, MD, PHD,*†‡ Steven E. Nissen, MD, FACC*
Cleveland, Ohio
Objectives This study sought to determine the relationship between coronary calcification and plaque progression in re-
sponse to established medical therapies.
Background Coronary calcification correlates with the extent of atherosclerosis and predicts clinical outcome.
Methods Atheroma volume was determined in serial intravascular ultrasound pullbacks in matched arterial segments of
776 patients with angiographic coronary artery disease. A calcium grade at baseline was assigned for each im-
age (total 28,876) (0  no calcium, 1  calcium with acoustic shadowing 90° and 2  calcium with shadow-
ing 90°). Patients with a calcium index (average of calcium scores in a pullback) below versus above the me-
dian were compared with regard to plaque burden and progression.
Results Patients with a high calcium index were older (59 vs. 54 years, p  0.001), more likely to be male (80% vs.
68%, p  0.001), and more likely to have a history of hypertension (71% vs. 64%, p  0.03). These patients had
a greater percentage atheroma volume (PAV) (45% vs. 34%, p  0.001), total atheroma volume (TAV) (210 vs.
151 mm3, p  0.001), and percentage of images with maximal plaque thickness 0.5 mm (93% vs. 72%, p 
0.001). The continuous rate of change in PAV (1.1  0.4% vs. 0.8  0.4%, p  0.34) and TAV (1.7  2.1% vs.
0.1  2.2%, p  0.37) was similar in patients with a lower and higher calcium index, respectively. A lower cal-
cium index was associated with a higher rate of patients showing substantial change in atheroma burden (at
least 5% change in PAV, 70% vs. 53%, p  0.001).
Conclusions Calcific plaques are more resistant to undergoing changes in size in response to systemic interventions tar-
geting atherosclerotic risk factors. (J Am Coll Cardiol 2007;49:263–70) © 2007 by the American College
of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.10.038a
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ihe significance of calcification in the genesis of atheroscle-
otic cardiovascular disease has received increasing atten-
ion. The calcified plaque has traditionally been regarded as
he most established atheroma within the arterial tree (1)
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006, accepted October 16, 2006.nd often presents a challenge for percutaneous interven-
ions (2). However, it has become apparent that plaque
alcification represents a dynamic process that is intimately
elated to the degree of inflammatory activity (3). A number
f inflammatory chemokines elaborated during atherogen-
sis stimulate the expression and activity of osteoblast-like
ells within the arterial wall that produce calcium (4–9).
See page 271
The conventional view that calcified atheromas are less
ikely to undergo fibrous cap rupture has been modified to
onsider the extent, location, and morphologic appearance
f calcification. In particular, microcalcification deposits in
he shoulder region of atheroma are associated with an
ncreased risk of fibrous cap rupture and subsequent isch-
mic events (10,11).
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Calcification and Plaque Progression January 16, 2007:263–70A number of imaging modal-
ities have been reported to detect
the degree of calcification within
the coronary arterial tree. In-
creasing amounts of calcification,
detected by computed tomogra-
phy, has been reported to predict
the presence and extent of ath-
erosclerotic plaque (12–15), in
addition to the likelihood of clin-
ical events (16,17). Investigations
are underway to understand how
best the noninvasive quantifica-
ion of coronary artery calcification can be integrated into
linical algorithms for cardiovascular risk stratification. Fur-
her, it remains unclear whether modifying the degree of
rogression of calcification in response to a number of
ystemic antiatherosclerotic therapies is associated with
linical benefit.
Intravascular ultrasound (IVUS) can image the entire
rterial wall, is well validated to assess the volumetric extent
f atheroma, and provides a limited characterization of its
egree of calcification (18). A number of studies have used
erial IVUS assessments of the arterial wall to show that
ntensive modification of atherosclerotic risk factors is asso-
iated with attenuation of plaque progression (19–21). The
urrent study investigated the relationship between the
egree of plaque calcification and both atheroma burden
nd its rate of progression in response to use of systemic
nterventions that target established risk factors.
ethods
election of patients. A retrospective analysis was per-
ormed of patients who participated in the REVERSAL
Reversal of Atherosclerosis with Aggressive Lipid Lower-
ng Therapy) (21) and CAMELOT (Comparison of Am-
odipine vs. Enalapril to Limit Occurences of Thrombosis)
20) studies. These studies assessed the impact of intensive
ipid-lowering and antihypertensive therapy on the rate of
oronary atherosclerotic plaque progression. These studies
nvolved serial assessment of a coronary arterial segment by
VUS using a standardized methodology and involved a
igh background rate of established medical therapies.
atients aged 30 to 75 years were identified as having
oronary artery disease on angiography, performed for
linical indications, with at least one 20% diameter stenosis
n a coronary artery. A target vessel was selected that had
ot undergone percutaneous intervention and had no lumi-
al stenosis 50% throughout a target segment of at least
0 mm in length. A central laboratory performed all
iochemical determinations (Medical Research Laboratory,
ighland Heights, Kentucky).
cquisition and analysis of IVUS images. The details of
VUS acquisition and analysis have been described in detail
Abbreviations
and Acronyms
EEM  external elastic
membrane
IVUS  intravascular
ultrasound
PAV  percentage
atheroma volume
RI  remodeling index
TAV  total atheroma
volumereviously (19–21). An IVUS catheter was advanced into ihe target vessel after administration of between 100 and
00 g of intracoronary nitroglycerin, and the transducer
as positioned distal to a side branch. The catheter was
ithdrawn through the target vessel by a motor drive at a
peed of 0.5 mm/s. Images were recorded on videotape at 30
rames/s. Cross-sectional images, spaced 1 mm apart in the
ullback from a distal to proximal fiduciary site, were
nalyzed in a blinded fashion. Using the National Institutes
f Health Image (version 1.62, National Institutes of
ealth public domain software, Bethesda, Maryland), man-
al planimetry was used to trace the leading edges of the
uminal and external elastic membrane (EEM) borders. A
egment was not measured if substantial artifact, presence of
n arterial side branch, or extensive calcification precluded
dequate planimetry of the EEM border. In the event that
n image could not be analyzed, the corresponding image
cquired at the other time point was not used for analysis.
THEROMA VOLUME. Total atheroma volume (TAV) was
alculated as the average of the differences between EEM
nd lumen areas across all evaluable slices and then normal-
zed to the length corresponding to the median number of
omparable slices in the whole population.
The need to normalize atheroma volume reflects the
eterogeneity in pullback length between patients because
his is determined by the anatomical location of the side
ranches defining the proximal and distal fiduciary points.
Percentage atheroma volume (PAV) representing the
roportion of the vessel volume occupied by atheroma was
alculated as the percentage of the sum of EEM areas
ccupied by TAV.
RTERIAL REMODELING. Remodeling was calculated in 3
ifferent ways: 1) Remodeling was characterized at the
ingle cross-sectional site containing the greatest amount of
laque. A remodeling index (RI) was calculated at the site
ontaining the greatest plaque area by calculating the ratio
f the EEM area at that site (lesion) compared with the
EM area at a reference site containing the least amount of
laque in the 10 mm proximal to this site. Remodeling was
ategorized as expansive (RI1.05), none (RI 0.95 to 1.05)
r constrictive (RI 0.95) at that site. 2) Remodeling was
haracterized throughout the entire arterial segment by
valuating EEM and lumen volumes. 3) The serial change
n remodeling was determined as the difference between RI,
EM, and lumen volumes at baseline and at completion of
he study.
XTENT OF CALCIUM. Calcification was assessed in 2 dif-
erent ways: 1) A calcium grade was assigned for each
easured image, which reflected the presence of calcium
nd degree of acoustic shadowing that resulted (0  no
alcium, 1  calcium with acoustic shadowing 90°, and 2
calcium with shadowing 90°). In images that contained
ultiple calcium deposits, the grade represented the sum-
ation of all angles of acoustic shadows present. A calciumndex was derived for each pullback by determining the
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January 16, 2007:263–70 Calcification and Plaque Progressionverage calcium grade of all measured images. For the
urpose of the current analysis, patients were stratified
ccording to having a calcium index less than or greater than
he median (0.26). The atheroma area was not calculated for
mages containing calcium with an acoustic shadow 90°
hat precluded accurate planimetry of the EEM leading
dge, resulting in exclusion of these images from volume
alculations. However, the calcium grade for these images
as included in the analysis. 2) The degree of calcification
as also expressed as the percentage of images containing
ny detectable calcium.
tatistical analysis. Continuous variables are expressed
s mean  SD (median) and categorical variables as
ercentage. C-reactive protein is expressed as median
interquartile range). Groups were compared using un-
aired t tests or Mann-Whitney log rank tests when the
ariable was not normally distributed. Correlations were
ssessed using Spearman rank-order correlation coeffi-
ients. To account for potential differences between the
ndividual studies in this pooled analysis, a random-
ffects model was used to determine changes in atheroma
olume in the groups. In addition to a volumetric
nalysis, patients were also classified as undergoing sub-
Clinical Characteristics of Subjects with a Calci
Table 1 Clinical Characteristics of Subjects
Parameter
Calcium
< Median
Age (yrs) 54.2 9.6
Male (%) 68
Caucasian (%) 88
Body mass index (kg/m2) 30.3 5.5
Hypertension (%) 63
Diabetes (%) 17
Metabolic syndrome (%) 37
Dyslipidemia (%) 96
Smoker (%) 23
Previous MI (%) 32
Previous CABG (%) 2
Previous PCI (%) 50
Baseline medications
Statin (%) 32
Beta-blocker (%) 65
Aspirin (%) 90
ACE Inhibitor (%) 31
Calcium channel blocker (%) 27
Baseline parameters
Total cholesterol (mg/dl) 214.1 43.
LDL cholesterol (mg/dl) 134.1 36.
HDL cholesterol (mg/dl) 42.3 12.
Triglycerides (mg/dl) 190.2 103
Systolic blood pressure (mm Hg) 130.5 16.
Diastolic blood pressure (mm Hg) 78.0 9.6
C-reactive protein (mg/l) 2.90 (1
Continuous variables expressed as mean SD (median) and categoric
(interquartile range).
ACE angiotensin-converting enzyme; CABG coronary artery bypa
myocardial infarction; PCI  percutaneous coronary intervention; SDtantial change (at least 5% relative change in PAV from 9aseline) or no substantial change (5% relative change
n PAV from baseline). A value of p  0.05 was
onsidered significant. All statistical analyses were per-
ormed using SAS software, version 8.2 (SAS Institute
nc., Cary, North Carolina).
esults
linical characteristics. Clinical characteristics, use of an-
iatherosclerotic therapies, and degree of risk factor control
re summarized in Table 1; 64.7% of patients participated in
he REVERSAL trial and 35.3% in the CAMELOT study.
atients with a calcium index greater than the median were
lder (58.6  9.1 years vs. 54.2  9.6 years, p  0.001),
ore likely to be male (80.4% vs. 68.1%, p  0.001), and
ore likely to have a history of hypertension (71.0% vs.
3.7%, p  0.03) or previous percutaneous intervention
62.8% vs. 50.1%, p  0.001). Patients with a greater
alcium index were more likely to have had a previous
yocardial infarction (38.4% vs. 32.4%, p 0.08), although
his failed to meet statistical significance. Patients with a
reater calcium index were more likely to receive a beta-
locker (77.1% vs. 65.8%, p 0.001) and aspirin (93.9% vs.
dex < or > Median
a Calcium Index < or > Median
83)
Calcium Index
> Median (n  393) p Value
58.6 9.1 (58) 0.001
80.4 0.001
91.6 0.19
30.4 5.9 (29.5) 0.67
71.0 0.03
19.3 0.45
37.2 0.96
95.2 0.31
27.2 0.29
38.4 0.08
4.1 0.11
62.8 0.001
33.6 0.78
77.1 0.001
93.9 0.09
33.3 0.50
32.6 0.12
) 213.3 43.0 (216.2) 0.81
.5) 134.3 36.8 (137) 0.78
41.2 10.2 (39) 0.49
8) 192.3 104.1 (166) 0.72
) 134.4 17.7 (134) 0.001
79.1 9.8 (80) 0.07
) 2.80 (1.60, 5.80) 0.72
bles expressed as percentage. C-reactive protein expressed as median
t; HDL high-density lipoprotein; LDL low-density lipoprotein; MI
ard deviation.um In
with
Index
(n  3
(53)
.1
.8
(29.3)
.7
.2
.3
.6
.8
.4
.1
.1
.6
.8
.6
.1
.4
6 (214
0 (136
1 (40)
.3 (16
3 (129
(79)
.2, 6.7
al varia0.6%, p  0.09), although the latter failed to meet
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Calcification and Plaque Progression January 16, 2007:263–70tatistical significance. The degree of risk factor control did
ot differ between the groups, except for a higher systolic
lood pressure (134.4  17.7 mm Hg vs. 130.5  16.3 mm
g, p 0.001) in the patients with a greater calcium index.
aseline atheroma burden. The relationship between cor-
nary artery calcification and atheroma burden at baseline is
ummarized in Table 2. Patients with a calcium index above
he median had a greater PAV (45.1  8.7% vs. 34.2 
.7%, p  0.001), normalized TAV (210.0  75.7 mm3 vs.
50.6  67.0 mm3, p  0.001), and percentage of images
hat contained plaque (defined as maximal plaque thickness
0.5 mm, 92.7 12.7% vs. 71.9 27.7%, p 0.001). The
ercentage of images containing calcium correlated posi-
ively with PAV (r  0.61, p  0.0001) and normalized
AV (r  0.47, p  0.0001).
aseline arterial wall remodeling. The relationship be-
ween arterial calcification and remodeling, at the site
ontaining the greatest amount of plaque and throughout
he pullback, is summarized in Table 3 and Figure 1. The
I at the most diseased site was lower in patients with a
alcium index above the median (0.94  0.21 vs. 0.97 
.22, p  0.03). This is consistent with the finding that
atients with a greater calcium index were more likely to
how constrictive remodeling (defined as an RI 0.95) at
his site (51.4% vs. 43.5%, p 0.03) at baseline. The degree
f calcification was also associated with arterial wall dimen-
ions throughout the pullback. Patients with a greater
alcium index had a smaller lumen volume (253.8  83.1
m3 vs. 286.8 101.8 mm3, p 0.001) and a larger EEM
olume (463.8 137.8 mm3 vs. 437.4 143.7 mm3 in high
nd low calcium groups respectively, p  0.009). This is
onsistent with the finding that the percentage of images
ontaining calcium correlated inversely with the lumen
olume (r  0.19, p  0.0001) and directly with EEM
olume (r  0.12, p  0.0007).
Baseline Atheroma Burden of Subjects With a C
Table 2 Baseline Atheroma Burden of Subje
Parameter
Calcium In
< Median (n 
Atheroma volume (%) 34.2 9.7 (3
Total atheroma volume (mm3) 150.6 67.0
Abnormal images (%)* 71.9 27.7
Worst-least 10-mm volume† 2.32 4.19
Length of pullback (mm) 36 14.2
Results expressed as mean  SD (median). *Abnormal image define
†Ratio of atheroma volume in the 10-mm segments containing the m
Baseline Remodeling Indices of Subjects With a
Table 3 Baseline Remodeling Indices of Sub
Parameter
Calcium Index
< Median (n  383
Remodeling index 0.97 0.22 (0.99)
EEM volume (mm3) 437.4 143.7 (419
Lumen volume (mm3) 286.8 101.8 (272
Results expressed as mean  SD (median). Remodeling index was ca
of plaque to the EEM area at a reference site containing the least amount of
EEM  external elastic membrane.isk factor control with therapy. The use of established
ntiatherosclerotic therapies and the degree of risk factor
ontrol are summarized in Table 4. Patients with a greater
alcium index were more likely to be treated with a
eta-blocker (81.7% vs. 70.0%, p  0.001) and less likely to
eceive a statin (94.1% vs. 97.1%, p  0.04). Apart from a
igher systolic blood pressure in patients with a greater
alcium index (131.5  13.3 mm Hg vs. 128.0  12.3 mm
g, p  0.001), the groups did not differ with regard to the
egree of risk factor control on therapy.
erial plaque progression and remodeling. The relation-
hip between baseline coronary artery calcification and rate
f change of plaque and remodeling, in response to use of
stablished medical therapies, is summarized in Table 5 and
igure 2. There was no correlation between the percentage
f images containing calcium at baseline and change in PAV
r  0.06, p  0.10) and normalized TAV (r  0.06, p
0.08) as continuous variables. As continuous variables,
here was no difference between the low-calcium and
igh-calcium groups with regard to changes in PAV (1.1 
.4% vs. 0.8  0.4%, p  0.34) and TAV (1.7  2.1% vs.
0.1  2.2%, p  0.37). However, patients who showed
vidence of substantial changes in PAV (5% relative
hange in either direction) had lower baseline calcium
ndices (median 0.21 vs. 0.38, p  0.001). A greater
roportion of patients with a baseline calcium index below
he median were likely to undergo a substantial change in
theroma burden (defined as at least a 5% change in PAV,
9.7% vs. 52.9%, p  0.001) (Fig. 2). On multivariate
nalysis, controlling for differences in clinical characteristics,
atients with a greater baseline calcium index remained less
ikely to undergo any substantial change in atheroma vol-
me (odds ratio 0.48, 95% confidence interval 0.35 to 0.66,
 0.0001). Similarly, patients with a lower calcium index
ere more likely to undergo substantial changes in atheroma
m Index < or > Median
ith a Calcium Index < or > Median
)
Calcium Index
> Median (n  393) p Value
45.1 8.7 (44.6) 0.001
) 210.0 75.7 (197.2) 0.001
92.7 12.7 (100) 0.001
1.78 2.18 (1.21) 0.001
38.4 14.7 (37) 0.02
ntaining a maximal plaque thickness 0.5 mm.
least amount of atheroma.
ium Index < or > Median
With a Calcium Index < or > Median
Calcium Index
> Median (n  393) p Value
0.94 0.21 (0.94) 0.03
463.8 137.8 (438.6) 0.009
253.8 83.1 (241.0) 0.001
as the ratio of the EEM area at the site containing the most amountalciu
cts W
dex
383
4.5)
(144.8
(80.6)
(1.44)
(34)Calc
jects
)
.1)
.4)
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plaque in the proximal 10 mm.
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January 16, 2007:263–70 Calcification and Plaque Progressionurden in response to intensive risk factor modification
Fig. 3). The groups did not differ with regard to the
eduction in RI at the site containing the greatest amount of
laque at baseline (0.05  0.01 vs. 0.04  0.01 in
ow-calcium and high-calcium groups respectively, p 
.53) (Table 5).
iscussion
he findings of the current study show that patients with
ore plaque calcification are less likely to undergo changes
n the amount of atheroma in response to use of medical
herapies that target established cardiovascular risk factors.
his occurred on the background of a positive relationship
etween the degree of calcification and both the extent and
iffuse nature of coronary atherosclerosis. These results have
Figure 1 Baseline Calcification and Arterial Remodeling
Percentage of subjects with a baseline calcium  median (solid bars) or 
median (open bars) who showed constrictive or expansive remodeling at the
site containing the greatest amount of plaque. *p  0.05 for comparison
between groups.
Use of Therapies and Risk Factor Controlof Subjects W th Calcium Index < or > Media
Table 4 Use of Therapies and Risk Factor Cof Subjects With a Calcium Index <
Parameter
Calcium
< Median
Concomitant medications
Statin (%) 97
Beta-blocker (%) 70
Aspirin (%) 93
ACE inhibitor (%) 33
Calcium channel blocker (%) 21
On-treatment parameters
Total cholesterol (mg/dl) 172.4 34
LDL cholesterol (mg/dl) 94.2 26
HDL cholesterol (mg/dl) 44.3 11
Triglycerides (mg/dl) 168.4 10
Systolic blood pressure (mm Hg) 128 12
Diastolic blood pressure (mm Hg) 77.1 7 (
C-reactive protein (mg/l) 2.0 (1.
Continuous variables expressed as mean SD (median) and categoric
(interquartile range).
Abbreviations as in Table 1.otential implications for the prediction of which patients
re likely to derive benefit from aggressive risk factor
odification.
The finding that greater degrees of calcium are associated
ith more extensive atheroma burden is consistent with
revious reports of a correlation between the amount of
laque and calcium on pathological studies (22) and a small
ohort studied by IVUS (23). This supports the traditional
iew that older and more established plaques are more likely
o calcify in response to a chronic pathological process (22).
t also highlights the relationship between the degree of
laque calcification and the pattern of arterial remodeling. A
arge number of pathological and imaging studies have
escribed the phenomenon whereby the arterial wall under-
oes changes in size and shape, termed remodeling, in
esponse to plaque accumulation (24,25). The typical re-
ponse of the arterial wall is to undergo expansion in
esponse to plaque deposition, in a process that initially
reserves luminal dimensions. Contraction of the arterial
all with subsequent shrinkage of the lumen, constrictive
emodeling, is more commonly seen in the presence of
hronic coronary artery disease (26). This is supported by
he current findings that patients with a greater amount of
laque calcium were more likely to show constrictive re-
odeling at the most diseased site, although contrasts with
l
Median
x
83)
Calcium Index
> Median (n  393) p Value
94.1 0.04
81.5 0.001
95.7 0.17
33.4 0.92
21.3 0.89
1.3) 170.8 35.8 (168.4) 0.67
) 93.3 29.6 (91) 0.65
) 43 10.6 (41.5) 0.10
43.8) 166 82.3 (144.8) 0.44
7) 131.5 13.3 (130) 0.001
77.5 7.2 (77) 0.46
2.0 (1.0, 5.0) 0.86
bles expressed as percentage. C-reactive protein expressed as median
erial Change in Atheroma Burden and Remodelingf Subjects With a Calcium Index < or > Me ian
Table 5 Serial Change in Atheroma Burden and Remodelingof Subjects With a Calcium Index < or > Median
Parameter
Calcium Index
< Median
(n  383)
Calcium Index
> Median
(n  393) p Value
Atheroma volume (%) 1.1 0.4 0.8 0.4 0.34
Total atheroma volume (mm3) 1.7 2.1 0.1 2.2 0.37
Remodeling index 0.05 0.01 0.04 0.01 0.53
esults expressed as least-square mean  SEM.n
ontro
or >
Inde
(n  3
.1
.0
.4
.8
.7
.5 (17
.3 (94
.7 (43
6.1 (1
.3 (12
77)
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Calcification and Plaque Progression January 16, 2007:263–70previous report that calcification did not differ between
ites with compensatory enlargement or focal contraction
27). It has been reported that culprit lesions with constric-
ive remodeling are typically found in the setting of stable
schemic syndromes (26). This provides further support for
he concept that calcified plaques might be more stable and
ess likely to rupture (28–31).
The current findings are in agreement with established
eports showing that the degree of coronary arterial calcifi-
ation, as determined by a range of noninvasive imaging
odalities, correlates with the extent of atherosclerotic
laque in pathological specimens (12–15). The ability of
VUS to visualize the entire vessel wall provides a unique
pportunity to precisely determine the correlation between
hese factors, in both a static and serial fashion, in vivo (18).
he results of the current study suggest that in response to
se of established medical therapies, the presence of greater
Figure 2 Baseline Calcification and Substantial
Change in Atheroma Burden
Mean baseline calcium index in subjects stratified according to degree of rela-
tive change in percentage atheroma volume (top) and mean  95% confidence
interval baseline calcium index in subjects stratified according to whether they
underwent substantial change (at least 5% change in percentage atheroma vol-
ume) or no substantial change (bottom). *p  0.001 for comparison between
groups.egrees of calcium at baseline are associated with lesshange in the extent of atherosclerotic plaque. This is
onsistent with the finding from pathological studies that
ore calcified plaques contain less lipidic and inflammatory
aterial (22). Given that flux of the lipidic, inflammatory,
nd necrotic components is likely to be more amenable to
odification by use of antiatherosclerotic therapies, it is not
urprising that more calcified lesions contain less of this
aterial and are therefore less likely to undergo significant
hanges in morphology.
This has important implications for the use of imaging
odalities that quantify coronary calcium in the assessment
Figure 3 Baseline Calcification and Substantial Change in
Atheroma Burden With Risk Factor Modification
Percentage of subjects with a baseline calcium index  median (solid bars) or
 median (open bars) who underwent substantial change in percentage ather-
oma volume stratified according to degree of modification of low-density
lipoprotein (LDL) cholesterol, systolic blood pressure (SBP), or C-reactive pro-
tein (CRP). *p  0.05, **p  0.01, and ***p  0.001 for comparison
between groups.
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January 16, 2007:263–70 Calcification and Plaque Progressionf antiatherosclerotic strategies. A number of reports have
merged describing the influence of lipid-lowering therapy
n the rate of change of coronary calcium. Although
owering low-density lipoprotein cholesterol with cerivasta-
in was reported to reduce the annual rate of progression of
oronary calcification (32), a number of groups have re-
orted that intensive lowering of low-density lipoprotein
holesterol has no effect (33,34). Given that the current
ndings suggest that more calcified lesions are less likely to
ndergo changes in size, despite a similar degree of risk
actor control with therapy, it must be questioned whether
he serial assessment of coronary calcification is the most
ptimal method for determining which patients are likely to
erive the greatest benefit from intensive risk factor modi-
cation or to assess the potential efficacy of experimental
gents.
A number of limitations should be noted. This is an
nalysis of pooled patient cohorts from 2 randomized
linical trials that used serial IVUS evaluation of coronary
theroma as the primary end point. All images were
nalyzed in the same core laboratory using well-validated
nd standardized techniques. The ability to pool data from
number of clinical trials provides a database of a large
umber of patients who have undergone serial assessments
f plaque burden. The impact of a high, but not universal,
se of established preventive medical therapies was assessed.
A number of analytical methods have been used to
uantify the degree of calcification. These include direct
easurement of the length and degree of arc of visualized
alcification, the degree of acoustic shadowing behind the
alcific deposit, and expression of the percentage of luminal
urface occupied by calcium as determined by videodensi-
ometry. The precision of each of these approaches is
nfluenced by a number of factors, including the physical
istance between the ultrasound transducer and site of
alcification. Regardless, it is clear that patients who have
ore calcium are less likely to undergo substantial changes
n the extent of coronary atherosclerosis.
It is not known whether the results can be applied to
atients older than the patients who participated in these
tudies. However, given that the degree of calcification
ncreases with age, the clinical utility of detecting calcium in
lderly patients is questionable. It should be noted that a
mall number of images could not be analyzed because of
xtensive calcification that precluded adequate measurement
f the EEM. Therefore, the difference in plaque burden
etween the 2 groups is likely to have been even greater.
urther, patients with extensive calcification throughout the
ength of the pullback at baseline were excluded from
articipating in the studies if an accurate determination of
theroma volume was not possible. Therefore, these extreme
evels of calcification were not included in the analysis.
iven their small number, it is unlikely that they would
ave had a significant impact on the findings. However, it
emains to be determined whether such heavily calcifiedesions are also resistant to undergoing changes in size in
esponse to established medical therapies.
Similarly, IVUS provides a very broad distinction of
laque composition, and in its current form it cannot
eliably quantify changes in lipidic, inflammatory, and
brotic components in response to systemic interventions. It
lso remains to be shown that changes in atheroma volume
n serial IVUS directly correlate with clinical outcome.
owever, it is possible that substantial changes in atheroma
re more likely to be clinically relevant for patients in terms
f cardiovascular event rates. Investigating this hypothesis is
eyond the scope of the current analysis.
In summary, patients with a greater amount of coronary
theroma calcification have more extensive plaque, which is
ess likely to undergo changes in response to intensive risk
actor modification. This has important implications for the
rediction of which patients are likely to derive the greatest
enefit from implementation of aggressive risk factor mod-
fication strategies.
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